MDXG stock forecast, quote, news & analysis
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone... Show more
Why MiMedx Group (MDXG) Stock Is Down -19.6% in the Last 30 Days
Key Takeaways
- MDXG declined roughly 19.6% over the past 30 days, sliding from a closing price of about $4.81 on September 21, 2026 to approximately $3.87.
- The selloff was driven primarily by an FTC "Second Request" issued on October 15, which extended antitrust review of MiMedx's planned acquisition of Sanara MedTech (SMTI).
- The move erased a late-September rally; over the trailing quarter the stock has been volatile and is down roughly 10% despite trading in a wide range between roughly $3.76 and $4.99.
- Operating results remain under pressure from the January 2026 Medicare reimbursement reduction, though the surgical franchise continues to grow.
- Analyst price targets have stayed constructive, but near-term deal and reimbursement uncertainty now dominate investor sentiment.
MiMedx Group (MDXG) Company Overview and Market Position
MiMedx Group, Inc. is a Marietta, Georgia-based pioneer in regenerative biomaterials, developing placental-derived (amniotic membrane) products used in wound care, burn, and surgical applications. Its portfolio includes well-known allografts such as EpiFix, AmnioFix, AmnioEffect, and Heliogen, alongside newer launches including EPIXPRESS, EMERGE, and G4Derm Plus. The company operates across two primary areas: its Wound & Surgical business and a fast-growing Surgical segment serving soft-tissue repair and orthopedic specialists.
MiMedx is among the leaders in amniotic tissue allografts and is followed by investors for its durable gross margins, strong cash generation, and efforts to diversify beyond reimbursement-sensitive wound care into higher-growth surgical markets. Its planned acquisition of Sanara MedTech is central to that strategy, aiming to nearly double surgical revenue and add complementary musculoskeletal and bone-fixation products.
MiMedx Group (MDXG) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MDXG fell about 19.6%, from a close of $4.81 on September 21, 2026 to roughly $3.87. The decline was concentrated in mid-to-late October, when the shares dropped from around $4.68 on October 15 to the low-$3.80s in subsequent sessions.
The trailing quarter tells a more volatile story. The stock entered the period near $4.32 in late July, dipped to an intraday low of roughly $3.76 around July 30 following second-quarter results and the Sanara announcement, then rallied through August and September to an intraday peak near $4.99 before reversing sharply in October. Net of that round trip, the shares are down roughly 10% over the quarter, reflecting a choppy, risk-driven trading pattern rather than a single-direction trend.
What Drove MDXG Stock Price in the Last 30 Days
The dominant catalyst was regulatory. On October 15, 2026, MiMedx and Sanara MedTech disclosed that each had received a "Second Request" from the Federal Trade Commission in connection with the FTC's review of their proposed merger. A Second Request extends the Hart-Scott-Rodino waiting period until 30 days after the parties substantially comply, effectively pushing the deal's expected close beyond its original year-end target and into 2027.
That disclosure triggered the sharp decline. The merger's cash-and-stock structure pays Sanara shareholders $33.00 in cash plus 0.4735 MiMedx shares, meaning the value of the deal is directly tied to MDXG's share price. As uncertainty about deal timing and completion rose, the merger arbitrage spread widened from roughly $0.13 per share to nearly $2.00, and both stocks sold off. No new quarterly earnings were released during the 30-day window, leaving the FTC development as the principal driver of the move.
What Drove MDXG Stock Performance Over the Last Quarter
The broader three-month narrative has been shaped by three forces. First, the January 1, 2026 Medicare reimbursement reduction continued to pressure the Wound Care business, contributing to a year-over-year decline in first-quarter sales and a cut in full-year 2026 revenue guidance to a range of $260 million to $290 million. Second, on July 29, MiMedx reported second-quarter results and announced its roughly $350 million acquisition of Sanara MedTech, sending MDXG down about 10% in after-hours trading as investors weighed the deal's debt financing and dilution against its strategic benefits.
Third, sentiment rebounded through late summer as analysts responded favorably. Lake Street raised its price target to $7 from $5 and Craig-Hallum to $8 from $6, citing the deal's accretion and cost synergies. That optimism carried the stock to its late-September highs before the October FTC Second Request reversed the momentum and reasserted deal-completion risk as the dominant theme.
Trending AI Robots
For investors seeking a data-driven edge, Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron operates hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. Each bot follows its own strategy, timeframe, and performance metrics, allowing traders to compare approaches that range from short-term momentum to longer-horizon trend signals. The curated view makes it easier to identify the robots currently generating the strongest results across the market. Exploring the Trending AI Robots page can help you discover automated strategies aligned with your own trading style.
MDXG Stock Forecast Drivers: What Investors Should Watch Next
Several factors will shape MDXG's direction in the months ahead. The most immediate is the FTC review of the Sanara transaction; the outcome and timing of the antitrust process will determine whether the deal closes on original terms, is renegotiated, or faces further delay. Investors should also watch third-quarter earnings and any update to 2026 guidance, particularly the trajectory of Wound Care volume recovery and the sustainability of Surgical growth.
On the regulatory and policy side, any corrective action from CMS on the WISeR prior-authorization model or other reimbursement relief could materially affect wound-care demand. Integration execution and realization of the projected $20 million-plus in cost synergies will matter if the merger closes, as will progress on Sanara's OsStic bone bioadhesive and MiMedx's own pipeline submissions. Broader small-cap healthcare sentiment and financing conditions round out the watchlist, but no single factor currently outweighs the pending merger review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MDXG's RSI Indicator is sitting in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for MDXG moved above the 200-day moving average on October 06, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +4.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXG advanced for three days, in 196 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
MDXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXG as a result. In 86 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for MDXG turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 27 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
MDXG moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDXG crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for MDXG entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. MDXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.527) is normal, around the industry mean (2.988). MDXG has a moderately high P/E Ratio (74.800) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1.985) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of patent protected regenerative biomaterial products and bioimplants
Industry Biotechnology